Antimalarials and SLE

Systemic Lupus Erythematosus, Fifth Edition

Volumn , Issue , 2010, Pages 1061-1081

  Costedoat Chalumeau, Nathalie ^a   Leroux, Gaëlle ^a   Piette, Jean Charles ^a   Amoura, Zahir ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858740508     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10057-9     Document Type: Chapter

References (153)

1. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus (1991) The Canadian Hydroxychloroquine Study Group. N Engl J Med 324(3), 150-154.
2. N. Kasitanon, D.M. Fine, M. Haas, L.S. Magder and M. Petri (2006) Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15(6), 366-370.
3. B.J. Fessler, G.S. Alarcon, G. McGwin Jr., J. Roseman, H.M. Bastian, A.W. Friedman, et al. (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52(5), 1473-1480.
4. D.J. Wallace (2000) Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 9(2), 81-82.
5. I. Cavazzana, R. Sala, C. Bazzani, A. Ceribelli, C. Zane, R. Cattaneo, et al. (2009) Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 18(8), 735-739.
6. E. Toubi, I. Rosner, M. Rozenbaum, A. Kessel and T.D. Golan (2000) The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9(2), 92-95.
7. M.L. Estes, D. Ewing-Wilson, S.M. Chou, H. Mitsumoto, M. Hanson, E. Shirey, et al. (1987) Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 82(3), 447-455.
8. M. Easterbrook (1999) An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol 26(9), 1866-1868.
9. N. Costedoat-Chalumeau, J.S. Hulot, Z. Amoura, A. Delcourt, T. Maisonobe, R. Dorent, et al. (2006) Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 107(2), 73-80.
10. E. Tsakonas, L. Joseph, J.M. Esdaile, D. Choquette, J.L. Senecal, A. Cividino, et al. (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7(2), 80-85.
11. R.A. Levy, V.S. Vilela, M.J. Cataldo, R.C. Ramos, J.L. Duarte, B.R. Tura, et al. (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10(6), 401-404.
12. I.M. Meinao, E.I. Sato, L.E. Andrade, M.B. Ferraz and E. Atra (1996) Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 5(3), 237-241.
13. M. Petri, G.S. Alarcon, R.P. Kimberly and J.D. Reveille (2005) Predictors of renal insufficiency in systemic lupus erythematosus (abstract). Arthritis Rheum
14. J.A. James, X.R. Kim-Howard, B.F. Bruner, M.K. Jonsson, M.T. McClain, M.R. Arbuckle, et al. (2007) Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16(6), 401-409.
15. G. Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron and M.A. Khamashta (2009) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis
16. M.H. Edwards, S. Pierangeli, X. Liu, J.H. Barker, G. Anderson and E.N. Harris (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96(12), 4380-4384.
17. M. Petri (1996) Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 25(4), 191-193.
18. M.Y. Mok, E.Y. Chan, D.Y. Fong, K.F. Leung, W.S. Wong and C.S. Lau (2005) Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 32(4), 622-628.
19. G. Ruiz-Irastorza, M.V. Egurbide, J.I. Pijoan, M. Garmendia, I. Villar, A. Martinez-Berriotxoa, et al. (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15(9), 577-583.
20. R. Kaiser, C.M. Cleveland and L.A. Criswell (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68(2), 238-241.
21. M.G. Tektonidou, K. Laskari, D.B. Panagiotakos and H.M. Moutsopoulos (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61(1), 29-36.
22. M.C. Wasko, H.B. Hubert, V.B. Lingala, J.R. Elliott, M.E. Luggen, J.F. Fries, et al. (2007) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. Jama 298(2), 187-193.
23. S. Lakshminarayanan, S. Walsh, M. Mohanraj and N. Rothfield (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28(1), 102-108.
24. C.C. Mok, A. Mak and K.M. Ma (2005) Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14(2), 106-112.
25. G. Ruiz-Irastorza, A. Ugarte, M.V. Egurbide, M. Garmendia, J.I. Pijoan, A. Martinez-Berriotxoa, et al. (2007) Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66(6), 815-817.
26. P. Rahman, D.D. Gladman, M.B. Urowitz, K. Yuen, D. Hallett and I.N. Bruce (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26(2), 325-330.
27. M. Petri, C. Lakatta, L. Magder and D. Goldman (1994) Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96(3), 254-259.
28. H.N. Hodis, F.P. Quismorio Jr., E. Wickham and D.H. Blankenhorn (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 20(4), 661-665.
29. D.J. Wallace, A.L. Metzger, V.J. Stecher, B.A. Turnbull and P.A. Kern (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89(3), 322-326.
30. R. Munro, E. Morrison, A.G. McDonald, J.A. Hunter, R. Madhok and H.A. Capell (1997) Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56(6), 374-377.
31. K.T. Ho, C.W. Ahn, G.S. Alarcon, B.A. Baethge, F.K. Tan, J. Roseman, et al. (2005) Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 44(10), 1303-1307.
32. J.H. Rand, X.X. Wu, A.S. Quinn, P.P. Chen, J.J. Hathcock and D.J. Taatjes (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112(5), 1687-1695.
33. N. Costedoat-Chalumeau, Z. Amoura, J.S. Hulot, H.A. Hammoud, G. Aymard, P. Cacoub, et al. (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54(10), 3284-3290.
34. K. Shojania, B.E. Koehler and T. Elliott (1999) Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 26(1), 195-196.
35. A. Quatraro, G. Consoli, M. Magno, F. Caretta, A. Nardozza, A. Ceriello, et al. (1990) Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 112(9), 678-681.
36. E.F. Borba and E. Bonfa (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28(4), 780-785.
37. L.S. Tam, E.K. Li, C.W. Lam and B. Tomlinson (2000) Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 9(6), 413-416.
38. A.C. Beynen, A.J. van der Molen and M.J. Geelen (1981) Inhibition of hepatic cholesterol biosynthesis by chloroquine. Lipids 16(6), 472-474.
39. T.A. Pagler, A. Neuhofer, H. Laggner, W. Strobl and H. Stangl (2007) Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaired. J Lipid Res 48(10), 2141-2150.
40. J.C. Sachet, E.F. Borba, E. Bonfa, C.G. Vinagre, V.M. Silva and R.C. Maranhao (2007) Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16(4), 273-278.
41. M.J. Roman, B.A. Shanker, A. Davis, M.D. Lockshin, L. Sammaritano, R. Simantov, et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25), 2399-2406.
42. J. Sotelo, E. Briceno and M.A. Lopez-Gonzalez (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144(5), 337-343.
43. R. Rahim and J.S. Strobl (2009) Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs
44. D.S. Fedson (2008) Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 8(9), 571-576.
45. J.M. Rolain, P. Colson and D. Raoult (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30(4), 297-308.
46. Y. Molad, A. Gorshtein, A.J. Wysenbeek, D. Guedj, R. Majadla, A. Weinberger, et al. (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11(6), 356-361.
47. G.J. Pons-Estel, G.S. Alarcon, G. McGwin Jr., M.I. Danila, J. Zhang, H.M. Bastian, et al. (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61(6), 830-839.
48. G.S. Alarcon, G. McGwin Jr., A.M. Bertoli, B.J. Fessler, J. Calvo-Alen, H.M. Bastian, et al. (2007) Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from lumina, a multiethnic us cohort (LUMINA L). Ann Rheum Dis 66(9), 1168-1172.
49. S. Ohkuma and B. Poole (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75(7), 3327-3331.
50. H.K. Ziegler and E.R. Unanue (1982) Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 79(1), 175-178.
51. F. Potvin, E. Petitclerc, F. Marceau and P.E. Poubelle (1997) Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immunol 158(4), 1872-1879.
52. P. Boya, R.A. Gonzalez-Polo, D. Poncet, K. Andreau, H.L. Vieira, T. Roumier, et al. (2003) Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22(25), 3927-3936.
53. L. Lagneaux, A. Delforge, M. Dejeneffe, M. Massy, M. Bernier and D. Bron (2002) Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma 43(5), 1087-1095.
54. J.H. Lai, L.J. Ho, K.C. Lu, D.M. Chang, M.F. Shaio and S.H. Han (2001) Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 166(11), 6914-6924.
55. X.W. Meng, J.M. Feller, J.B. Ziegler, S.M. Pittman and C.M. Ireland (1997) Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 40(5), 927-935.
56. W.U. Kim, S.A. Yoo, S.Y. Min, S.H. Park, H.S. Koh, S.W. Song, et al. (2006) Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 144(3), 503-511.
57. S.T. Liu, C.R. Wang, G.D. Yin, M.F. Liu, G.L. Lee, M.Y. Chen, et al. (2001) Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 19(1), 29-35.
58. K. Sperber, H. Quraishi, T.H. Kalb, A. Panja, V. Stecher and L. Mayer (1993) Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 20(5), 803-808.
59. A.L. Gilman, F. Beams, M. Tefft and A. Mazumder (1996) The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplant 17(6), 1069-1075.
60. F.D. Goldman, A.L. Gilman, C. Hollenback, R.M. Kato, B.A. Premack and D.J. Rawlings (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 95(11), 3460-3466.
61. R.B. Landewe, A.M. Miltenburg, M.J. Verdonk, C.L. Verweij, F.C. Breedveld, M.R. Daha, et al. (1995) Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 102(1), 144-151.
62. K.R. Schultz, S. Bader, D. Nelson, M.D. Wang and K.T. HayGlass (1997) Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist? Transplantation 64(7), 1055-1065.
63. S. Picot, F. Peyron, J.P. Vuillez, B. Polack and P. Ambroise-Thomas (1991) Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro. J Infect Dis 164(4), 830.
64. S. Namiuchi, S. Kumagai, H. Imura, T. Suginoshita, T. Hattori and F. Hirata (1984) Quinacrine inhibits the primary but not secondary proliferative response of human cytotoxic T cells to allogeneic non-T cell antigens. J Immunol 132(3), 1456-1461.
65. B.E. van den Borne, B.A. Dijkmans, H.H. de Rooij, S. le Cessie and C.L. Verweij (1997) Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 24(1), 55-60.
66. M. Tishler, I. Yaron, I. Shirazi and M. Yaron (1999) Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58(4), 253-256.
67. J. Bondeson and R. Sundler (1998) Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 30(3), 357-366.
68. S.N. Cohen and K.L. Yielding (1965) Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc Natl Acad Sci USA 54(2), 521-527.
69. A. Filippov, G. Skatova, V. Porotikov, E. Kobrinsky and M. Saxon (1989) Ca2+-antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine. Gen Physiol Biophys 8(2), 113-118.
70. R. Lafyatis, M. York and A. Marshak-Rothstein (2006) Antimalarial agents: Closing the gate on toll-like receptors? Arthritis Rheum 54(10), 3068-3070.
71. F. Brentano, O. Schorr, R.E. Gay, S. Gay and D. Kyburz (2005) RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 52(9), 2656-2665.
72. D. Kyburz, F. Brentano and S. Gay (2006) Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2(9), 458-459.
73. E.A. Leadbetter, I.R. Rifkin, A.M. Hohlbaum, B.C. Beaudette, M.J. Shlomchik and A. Marshak-Rothstein (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416(6881), 603-607.
74. J. Jimenez-Alonso, J. Tercedor, L. Jaimez and E. Garcia-Lora (1998) Antimalarial drug-induced aquagenic-type pruritus in patients with lupus. Arthritis Rheum 41(4), 744-745.
75. Physician’s Desk Reference. 2005 [cited 2005; Available from:
76. J.A. Avina-Zubieta, G. Galindo-Rodriguez, S. Newman, M.E. Suarez-Almazor and A.S. Russell (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57(10), 582-587.
77. M.F. Marmor (2003) New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 48(6), 1764.
78. M.F. Marmor (2005) The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am J Ophthalmol 140(5), 894-895.
79. G.D. Levy, S.J. Munz, J. Paschal, H.B. Cohen, K.J. Pince and T. Peterson (1997) Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 40(8), 1482-1486.
80. M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo and W.F. Mieler (2002) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109(7), 1377-1382.
81. A.E. Semmer, M.S. Lee, A.R. Harrison and T.W. Olsen (2008) Hydroxychloroquine retinopathy screening. Br J Ophthalmol 92(12), 1653-1655.
82. F. Rigaudiere, I. Ingster-Moati, J.C. Hache, J. Leid, R. Verdet, P. Haymann, et al. (2004) [Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment]. J Fr Ophtalmol 27(2), 191-199.
83. V.A. Manohar, K.G. Moder, W.D. Edwards and K. Klarich (2009) Restrictive cardiomyopathy secondary to hydroxychloroquine therapy. J Rheumatol 36(2), 440-441.
84. T.R. Soong, L.A. Barouch, H.C. Champion, F.M. Wigley and M.K. Halushka (2007) New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy–a report of 2 cases. Hum Pathol 38(12), 1858-1863.
85. P. Godeau, L. Guillevin, J. Fechner, O. Bletry and G. Herreman (1981) [Disorders of conduction in lupus erythematosus: frequency and incidence in a group of 112 patients]. Ann Med Interne (Paris) 132(4), 234-240.
86. N. Costedoat-Chalumeau, J.S. Hulot, Z. Amoura, G. Leroux, P. Lechat, C. Funck-Brentano, et al. (2007) Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 46(5), 808-810.
87. A. Sghirlanzoni, R. Mantegazza, M. Mora, D. Pareyson and F. Cornelio (1988) Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve 11(2), 114-119.
88. M. Stein, M.J. Bell and L.C. Ang (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27(12), 2927-2931.
89. A.K. Siddiqui, S.I. Huberfeld, K.M. Weidenheim, K.R. Einberg and L.S. Efferen (2007) Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 131(2), 588-590.
90. M.J. Van Beek and W.W. Piette (2001) Antimalarials. Dermatol Clin 19(1), 147-160. ix
91. T. Munster, J.P. Gibbs, D. Shen, B.A. Baethge, G.R. Botstein, J. Caldwell, et al. (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46(6), 1460-1469.
92. P.K. Puri, N.I. Lountzis, W. Tyler and T. Ferringer (2008) Hydroxychloroquine-induced hyperpigmentation: the staining pattern. J Cutan Pathol 35(12), 1134-1137.
93. S. Kalia and J.P. Dutz (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20(4), 160-174.
94. S. Meller, P.A. Gerber and B. Homey (2008) Clinical image: blonde by prescription. Arthritis Rheum 58(8), 2286.
95. U. Gul, S.K. Cakmak, A. Kilic, M. Gonul and S. Bilgili (2006) A case of hydroxychloroquine induced pruritus. Eur J Dermatol 16(5), 586-587.
96. S. Sorbara, E. Cozzani, A. Rebora and A. Parodi (2006) Hydroxychloroquine in psoriasis: is it really harmful? Acta Derm Venereol 86(5), 450-451.
97. S.M. Herman, M.H. Shin, A. Holbrook and D. Rosenthal (2006) The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol 7(4), 249-257.
98. G.M. Kammer, N.A. Soter, D.J. Gibson and P.H. Schur (1979) Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 9(2), 75-97.
99. R. Wolf and V. Ruocco (1999) Triggered psoriasis. Adv Exp Med Biol 455 221-225.
100. R. Wolf, A.L. Schiavo, M.L. Lombardi, F. de Angelis and V. Ruocco (1999) The in vitro effect of hydroxychloroquine on skin morphology in psoriasis. Int J Dermatol 38(2), 154-157.
101. M. Mates, S. Zevin, G.S. Breuer, P. Navon and G. Nesher (2006) Desensitization to hydroxychloroquine—experience of 4 patients. J Rheumatol 33(4), 814-816.
102. D. Chernof and K.S. Taylor (1968) Hydroxychloroquine-induced agranulocytosis. Arch Dermatol 97(2), 163-164.
103. R.P. Propp and J.S. Stillman (1967) Agranulocytosis and hydroxychloroquine. N Engl J Med 277(9), 492-493.
104. V. Ferraro, F. Mantoux, K. Denis, M.A. Lay-Macagno, J.P. Ortonne and J.P. Lacour (2004) [Hallucinations during treatment with hydrochloroquine]. Ann Dermatol Venereol 131(5), 471-473.
105. W.Q. Ward, W.G. Walter-Ryan and G.M. Shehi (1985) Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol 12(5 Pt 1), 863-865.
106. D.U. Cansu and C. Korkmaz (2008) Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 47(3), 378-379.
107. R. Roubenoff, J. Hoyt, M. Petri, M.C. Hochberg and D.B. Hellmann (1988) Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 18(2), 88-110.
108. P.A. Phillips-Howard and D. Wood (1996) The safety of antimalarial drugs in pregnancy. Drug Saf 14(3), 131-145.
109. G.J. Matz and R.F. Naunton (1968) Ototoxicity of chloroquine. Arch Otolaryngol 88(4), 370-372.
110. N. Costedoat-Chalumeau, Z. Amoura, G. Aymard, T.H. Le, B. Wechsler, D. Vauthier, et al. (2002) Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 46(4), 1123-1124.
111. A.L. Parke (1988) Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 15(4), 607-610.
112. A. Parke (1988) Antimalarial drugs and pregnancy. Am J Med 85(4A), 30-33.
113. A. Parke and B. West (1996) Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 23(10), 1715-1718.
114. N.M. Buchanan, E. Toubi, M.A. Khamashta, F. Lima, S. Kerslake and G.R. Hughes (1996) Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 55(7), 486-488.
115. M. Motta, A. Tincani, D. Faden, E. Zinzini and G. Chirico (2002) Antimalarial agents in pregnancy. Lancet 359(9305), 524-525.
116. G. Klinger, Y. Morad, C.A. Westall, C. Laskin, K.A. Spitzer, G. Koren, et al. (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358(9284), 813-814.
117. M.E. Clowse, L. Magder, F. Witter and M. Petri (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54(11), 3640-3647.
118. N. Costedoat-Chalumeau, Z. Amoura, P. Duhaut, L.T. Huong du, D. Sebbough, B. Wechsler, et al. (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48(11), 3207-3211.
119. K. Sperber, C. Hom, C.P. Chao, D. Shapiro and J. Ash (2009) Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 7 9.
120. M. Frassi, C. Biasini, M. Taglietti, E. Danieli, D. Faden, A. Lojacono, et al. (2004) Hydroxychloroquine in pregnant patients with rheumatic disease: a case control observation of 76 treated pregnancies (abstract). Lupus 13(9), 755.
121. M.E. Clowse, L.S. Magder and M. Petri (2004) The Effect of Hydroxychloroquine on Pregnancy Outcomes and Disease Activity in Lupus Patients (abstract). Arthritis Rheum 50 689-690.
122. R. Cimaz, A. Brucato, E. Meregalli, M. Muscara and P. Sergi (2004) Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum 50(9), 3056-3057. author reply 7–8
123. N. Costedoat-Chalumeau, Z. Amoura, D. Sebbough and J.C. Piette (2004) Reply. Arthritis Rheum 50(9), 3057.
124. M. Motta, A. Tincani, D. Faden, E. Zinzini, A. Lojacono, A. Marchesi, et al. (2004) Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 14 14.
125. F. Renault, R. Flores-Guevara, C. Renaud, P. Richard, A.I. Vermersch and F. Gold (2009) Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 98(9), 1500-1503.
126. R.L. Nation, L.P. Hackett, L.J. Dusci and K.F. Ilett (1984) Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 17(3), 368-369.
127. M. Ostensen, M. Khamashta, M. Lockshin, A. Parke, A. Brucato, H. Carp, et al. (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8(3), 209.
128. P.R. Fischer and E. Walker (2002) Myasthenia and malaria medicines. J Travel Med 9(5), 267-268.
129. G.E. Gibson and M.T. McEvoy (1998) Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients. J Am Acad Dermatol 38(4), 569-573.
130. P. Harper and S. Wahlin (2007) Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 10(6), 444-455.
131. G. Sjolin-Forsberg, B. Berne, C. Blixt, M. Johansson and B. Lindstrom (1993) Chloroquine phosphate: a long-term follow-up of drug concentrations in skin suction blister fluid and plasma. Acta Derm Venereol 73(6), 426-429.
132. S.J. Carmichael, B. Charles and S.E. Tett (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25(6), 671-681.
133. S.E. Tett, D.J. Cutler, R.O. Day and K.F. Brown (1988) A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 26(3), 303-313.
134. D.J. Cutler, A.C. MacIntyre and S.E. Tett (1988) Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl 24 142-157.
135. S.E. Tett, D.J. Cutler, C. Beck and R.O. Day (2000) Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis—a prospective, dose ranging study. J Rheumatol 27(7), 1656-1660.
136. S.E. Tett, R.O. Day and D.J. Cutler (1993) Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study. J Rheumatol 20(11), 1874-1879.
137. S.E. Tett, D.J. Cutler and R.O. Day (1992) Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci 81(2), 155-159.
138. S.E. Tett, D.J. Cutler, R.O. Day and K.F. Brown (1989) Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 27(6), 771-779.
139. S. Tett, R. Day and D. Cutler (1996) Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol 41(3), 244-246.
140. A.J. McLachlan, S.E. Tett, D.J. Cutler and R.O. Day (1994) Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. Chirality 6(4), 360-364.
141. D.R. Miller, S.K. Khalil and G.A. Nygard (1991) Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. Dicp 25(12), 1302-1305.
142. N. Costedoat-Chalumeau, Z. Amoura, J.S. Hulot, G. Aymard, G. Leroux, H.A. Hammoud, et al. (2007) Very low blood hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 66(6), 821-824.
143. Micromedex® Healthcare Series; http://www.thomsonhc.com/hcs/librarian. Access 2009.
144. M. Somer, J. Kallio, U. Pesonen, K. Pyykko, R. Huupponen and M. Scheinin (2000) Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 49(6), 549-554.
145. A. Jamshidzadeh, H. Niknahad and H. Kashafi (2007) Cytotoxicity of chloroquine in isolated rat hepatocytes. J Appl Toxicol 27(4), 322-326.
146. M.R. Namazi (2009) The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. Lupus 18(2), 104-105.
147. G. Leroux, N. Costedoat-Chalumeau, J.S. Hulot, Z. Amoura, C. Frances, G. Aymard, et al. (2007) Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann Rheum Dis 66(11), 1547-1548.
148. E.R. Smith and W. Klein-Schwartz (2005) Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 28(4), 437-443.
149. R.K. Burt, A. Traynor, L. Statkute, W.G. Barr, R. Rosa, J. Schroeder, et al. (2006) Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. Jama 295(5), 527-535.
150. J. Sanchez-Guerrero, A.G. Uribe, L. Jimenez-Santana, M. Mestanza-Peralta, P. Lara-Reyes, A.H. Seuc, et al. (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353(24), 2539-2549.
151. M. Petri, M.Y. Kim, K.C. Kalunian, J. Grossman, B.H. Hahn, L.R. Sammaritano, et al. (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24), 2550-2558.
152. E.M. Ginzler, M.A. Dooley, C. Aranow, M.Y. Kim, J. Buyon, J.T. Merrill, et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353(21), 2219-2228.
153. M.Y. Karim, P. Alba, M.J. Cuadrado, I.C. Abbs, D.P. D’Cruz, M.A. Khamashta, et al. (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41(8), 876-882.